CN Bio PhysioMimix Organ-on-a-Chip data supports Inipharm’s INI-822 for metabolic liver disease treatment now in clinical testing Post author: Post published:December 4, 2023 Post category:uncategorized CN Bio today announced its PhysioMimix® assay for Non-alcoholic steatohepatitis (NASH). You Might Also Like Study highlights disparities in lung cancer treatment access across Europe March 4, 2024 GLP-1 drugs may reduce pancreatitis risk in obese and diabetic patients June 3, 2024 A long-term ketogenic diet accumulates aged cells in normal tissues, study finds May 23, 2024